fce 28260 fce 28260 fce 28260 is an azasteroidal 5α-reductase inhibitor which was developed for the treatment of benign prostatic hyperplasia and androgenic alopecia (pattern hair loss) in the 1990s but was never marketed. fce 28260 has been found to inhibit rat and human 5α-reductase with half-maximal inhibitory concentrations (ic50) of 15 and 16 nm, respectively, while finasteride had values of 30 and 52 nm. fce 28260clinical dataother namespnu 156765routes ofadministrationoralatc codenoneidentifiers iupac name (4ar,4bs,6as,7s,9as,9bs,11ar)-4a,6a-dimethyl-2-oxo-n-((2rs)-1,1,1-trifluoro-2-phenyl-2-propanyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1h-indenoquinoline-7-carboxamide cas number155651-56-2 ychemspider117369uniihp9c5lm7nxchemical and physical dataformulac28h35f3n2o2molar mass488.595 g·mol−13d model (jsmol)interactive image smiles fc(f)(f)c(c1ccccc1)(nc(=o)32(cc4(2cc3)cc5nc(=o)\c=c/45c)c)c inchi inchi=1s/c28h35f3n2o2/c1-25-15-13-20-18(9-12-22-26(20,2)16-14-23(34)32-22)19(25)10-11-21(25)24(35)33-27(3,28(29,30)31)17-7-5-4-6-8-17/h4-8,14,16,18-22h,9-13,15h2,1-3h3,(h,32,34)(h,33,35)/t18-,19-,20-,21+,22+,25-,26+,27?/m0/s1key:faizuawlkohmop-zoixlqffsa-n